Logo image of TNG.PA

TRANSGENE SA (TNG.PA) Stock Fundamental Analysis

Europe - EPA:TNG - FR0005175080 - Common Stock

1.15 EUR
-0.07 (-5.74%)
Last: 9/15/2025, 5:25:41 PM
Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to TNG. TNG was compared to 75 industry peers in the Biotechnology industry. TNG may be in some trouble as it scores bad on both profitability and health. TNG is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

TNG had negative earnings in the past year.
In the past year TNG has reported a negative cash flow from operations.
In the past 5 years TNG always reported negative net income.
In the past 5 years TNG always reported negative operating cash flow.
TNG.PA Yearly Net Income VS EBIT VS OCF VS FCFTNG.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -10M -20M -30M -40M

1.2 Ratios

Looking at the Return On Assets, with a value of -43.99%, TNG is doing worse than 61.33% of the companies in the same industry.
Industry RankSector Rank
ROA -43.99%
ROE N/A
ROIC N/A
ROA(3y)-39.31%
ROA(5y)-30.88%
ROE(3y)-86.26%
ROE(5y)-64.34%
ROIC(3y)N/A
ROIC(5y)N/A
TNG.PA Yearly ROA, ROE, ROICTNG.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -50 -100 -150

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for TNG so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
TNG.PA Yearly Profit, Operating, Gross MarginsTNG.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 100 -100 -200 -300 -400

More info and screens

2

2. Health

2.1 Basic Checks

TNG does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for TNG has been increased compared to 1 year ago.
The number of shares outstanding for TNG has been increased compared to 5 years ago.
TNG has a better debt/assets ratio than last year.
TNG.PA Yearly Shares OutstandingTNG.PA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M 100M
TNG.PA Yearly Total Debt VS Total AssetsTNG.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M 100M

2.2 Solvency

Based on the Altman-Z score of -3.12, we must say that TNG is in the distress zone and has some risk of bankruptcy.
TNG has a Altman-Z score of -3.12. This is in the lower half of the industry: TNG underperforms 64.00% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -3.12
ROIC/WACCN/A
WACC7.83%
TNG.PA Yearly LT Debt VS Equity VS FCFTNG.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20M -20M 40M -40M 60M

2.3 Liquidity

TNG has a Current Ratio of 1.57. This is a normal value and indicates that TNG is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 1.57, TNG is in line with its industry, outperforming 41.33% of the companies in the same industry.
TNG has a Quick Ratio of 1.57. This is a normal value and indicates that TNG is financially healthy and should not expect problems in meeting its short term obligations.
The Quick ratio of TNG (1.57) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 1.57
Quick Ratio 1.57
TNG.PA Yearly Current Assets VS Current LiabilitesTNG.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M

More info and screens

3

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 32.67% over the past year.
TNG shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -23.68%.
TNG shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 1.51% yearly.
EPS 1Y (TTM)32.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
Revenue 1Y (TTM)-23.68%
Revenue growth 3Y-6.51%
Revenue growth 5Y1.51%
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 1.08% on average over the next years.
The Revenue is expected to grow by 1.88% on average over the next years.
EPS Next Y28%
EPS Next 2Y46.52%
EPS Next 3Y0.88%
EPS Next 5Y1.08%
Revenue Next Year-44.69%
Revenue Next 2Y-33.54%
Revenue Next 3Y-17.5%
Revenue Next 5Y1.88%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
TNG.PA Yearly Revenue VS EstimatesTNG.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 10M 20M 30M 40M 50M
TNG.PA Yearly EPS VS EstimatesTNG.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -0.2 -0.4 -0.6 -0.8 -1

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for TNG. In the last year negative earnings were reported.
TNG is valuated rather expensively with a Price/Forward Earnings ratio of 20.70.
78.67% of the companies in the same industry are more expensive than TNG, based on the Price/Forward Earnings ratio.
TNG's Price/Forward Earnings ratio indicates a similar valuation than the S&P500 average which is at 22.73.
Industry RankSector Rank
PE N/A
Fwd PE 20.7
TNG.PA Price Earnings VS Forward Price EarningsTNG.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
TNG.PA Per share dataTNG.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.1 -0.2

4.3 Compensation for Growth

TNG's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y46.52%
EPS Next 3Y0.88%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for TNG!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

TRANSGENE SA

EPA:TNG (9/15/2025, 5:25:41 PM)

1.15

-0.07 (-5.74%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)04-24 2025-04-24
Earnings (Next)09-16 2025-09-16
Inst Owners0.74%
Inst Owner ChangeN/A
Ins Owners0.7%
Ins Owner ChangeN/A
Market Cap152.65M
Analysts82.86
Price Target1.73 (50.43%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 20.7
P/S 20
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.22
EYN/A
EPS(NY)0.06
Fwd EY4.83%
FCF(TTM)-0.29
FCFYN/A
OCF(TTM)-0.27
OCFYN/A
SpS0.06
BVpS0
TBVpS-0.01
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -43.99%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-39.31%
ROA(5y)-30.88%
ROE(3y)-86.26%
ROE(5y)-64.34%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.15
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 237.06%
Cap/Sales 42.82%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.57
Quick Ratio 1.57
Altman-Z -3.12
F-Score3
WACC7.83%
ROIC/WACCN/A
Cap/Depr(3y)95.02%
Cap/Depr(5y)109.94%
Cap/Sales(3y)17.95%
Cap/Sales(5y)15.04%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)32.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
EPS Next Y28%
EPS Next 2Y46.52%
EPS Next 3Y0.88%
EPS Next 5Y1.08%
Revenue 1Y (TTM)-23.68%
Revenue growth 3Y-6.51%
Revenue growth 5Y1.51%
Sales Q2Q%N/A
Revenue Next Year-44.69%
Revenue Next 2Y-33.54%
Revenue Next 3Y-17.5%
Revenue Next 5Y1.88%
EBIT growth 1Y-0.38%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year2.8%
EBIT Next 3Y-17.24%
EBIT Next 5Y-16.88%
FCF growth 1Y-157.45%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-143.79%
OCF growth 3YN/A
OCF growth 5YN/A